The TGA will become the single agency responsible for receiving and handling complaints about the advertising of medicines and medical devices from 1 July 2018.
The reform aims to increase safety for consumers and improve public confidence in the system by reducing the current complexity and inconsistencies around advertising of therapeutic goods.
Complaints are currently considered by the Complaints Resolution Panel, multiple industry associations or the TGA depending on the type of product and advertising medium.
Currently some advertisements require pre-approval and others do not – again on the basis of product and medium.
Arising from one of 58 recommendations in last year’s ., the reform will also strengthen the TGA’s investigation and enforcement powers.
The public can also expect more timely resolution of complaints while industry can expect stronger penalties and sanctions for any breaches.